Table 3.
Papers describing exclusively limited disease and extensive disease
| Author | Institution | N | Stage | Chemotherapy | RXT | S | Chemo | Chemo/RXT | Chemo/S | S/RXT | S/Chemo/RXT | RR | mOS | Local Recurrence |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| *Kalaiah70 | Creighton University | 132 | 77% LD | NA | --- | 27 (26%) | 4 (4%) | 4/16 (16%) | 2 neoadjuvant (2%) | 2 (2%) | 14 (14%) | NA | LD: 13.4m | NA |
| 23% ED | --- | 8 (27%) | 5 (17%) | 32 adjuvant (31%) | 3 (10%) | 2 (7%) | ED: 4.2m | |||||||
| Mukesh71 | Addenbrooke’s Hospital NHS Trust, Cambridge | 20 | 55% LD | CMV; CaE; CAV; GC | 1 (9%) | 1 (9%) | 1 (9%) | 4 (36%) | 4 adj (13%) | --- | --- | NA | All: 10m All chemo: | 0 |
| 45% ED | 1 (11%) | 4 (44%) | 3 (33%) | 2 (22%) | 1 neoadjuvant (9%) | --- | --- | 33m All non- | ||||||
| Siefker-Radtke-Phase 231 | MD Anderson | 30 | 60% LD | alternating doublet chemotherapy IA and EP | --- | --- | --- | --- | 1 adjuvant (9%) | --- | --- | downs 78% 100% RR | Neo: 58m | NA |
| 40% ED | --- | 9 (75%) | --- | --- | --- | --- | --- | Met: 13.3m | ||||||
| Asmis76 | The Ottawa Hospital Regional Cancer Center | 12 | 66% LD | EP or CaE | 1 (12%) | TURBT (100%) | --- | 5 (63%) | 18 neoadjuvant (100%) | --- | 1 (12%) | NA | All: 19.8m | NA |
| 34% ED | --- | 1 (25%) | 2 (50%) | 3 neoadjuvant (25%) | --- | --- | ||||||||
| Bex-Prospective28 | The Netherlands Cancer Institute | 25 | 68% LD | cisplatin, doxorubicin, and etoposide; ifosfamide, cisplatin, and etoposide; EP; MVAC | 5 (29%) | 2 (12%) | 2 (12%) | 8* (47%) | 1 (13%) | --- | --- | 11 CR (85%) | All: 8m Chemo: 15m No chemo: 4m | 1 (6%) |
| 32% ED | 3 (37%) | --- | --- | --- | --- | --- | LD: 12m ED: 5m |
--- | ||||||
| Choong22 | Mayo Clinic | 44 | 57% stage 2–3 | several combination-all 1st line platinum based | --- | 19 (76%) | --- | 1 (4%) | --- | 2 (8%) | --- | NA | All: 20 months | NA |
| 1*(4%) | --- | --- | ||||||||||||
| 43% stage | --- | 2 (11%) | 5 (26%) | 1 neoadjuvant (4%) | 1 (5%) | |||||||||
| Cheng20 | Indiana University | 64 | 52% T3+T4 | EP; CaE; others | 10 (16%) | 38 (60%) | 36 (57%) | --- | 2 adjuvant (8%) | --- | --- | NA | >12m | NA |
| --- | 10 adjuvant (52%) | --- | --- | |||||||||||
| Abrahams23 | MD Anderson | 41 | 73% stage 1–3 | NA | --- | 9 (30%) | --- | --- | --- | --- | --- | NA | All: 23m | NA |
| 27% stage 4 | --- | --- | 7 (64%) | --- | --- | --- | --- |
LD: limited disease; ED: extensive disease; S: surgery; Chemo: chemotherapy; Chemo/RXT: chemotherapy combined to radiotherapy; Chemo/S: chemotherapy combined to surgery; S/RXT: surgery combined to radiotherapy; S/Chemo/RXT: surgery combine to chemoradiation; RR: response rate; mOS: median overall survival; downs: downstaging; CR: complete response, met: metastatic disease; NA: not available; met: in the group with metastatic disease; TURBT: Transurethral bladder tumour resection; EP: cisplatin+etoposide; CAV: cyclophosphamide+doxorubicin+vincristine; CG: gemcitabine+cisplatin; IA: ifosfamide+doxorubicin; MVAC: methotrexate+vinblastine+adriamycin+cisplatin; CaE: carboplatin+etoposide; CMV: cyclophosphamide+methotrexate+vinblastine.
Had prior transurethral resection of bladder tumour.